This clinical trial is focused on patients with cirrhosis, a condition where the liver is severely damaged and scarred. The study involves patients who are hospitalized with a sudden worsening of their cirrhosis, known as decompensated cirrhosis, and have a bacterial infection that has been present for 48 hours or less. The trial will compare two different approaches to treating these infections: a conventional antibiotic strategy and a strategy guided by monitoring the spread of bacteria in the hospital environment.

The treatment being studied includes the use of Norfloxacin, an antibiotic that comes in tablet form. The purpose of the study is to evaluate how likely it is for patients to develop resistance to antibiotics within 28 days of starting treatment. This will be assessed by looking for new bacterial infections or colonizations that are resistant to multiple drugs, known as MDROs (multi-drug resistant organisms).

Participants in the study will receive either the conventional antibiotic treatment or the new strategy based on hospital bacteria monitoring. The study will track various outcomes, such as the development of antibiotic resistance, the resolution of infections, and the overall health and survival of the patients during their hospital stay and up to 28 days after treatment begins. The trial aims to provide insights into the best ways to manage bacterial infections in patients with decompensated cirrhosis, potentially improving treatment strategies and patient outcomes.